Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Funding To Give ViroMed ‘Favorable Position’ For Gene Therapy Deal

Executive Summary

ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.


Related Content

A Peek Into Korean Bioventures’ Success Factors, Challenges
Genexine Raises New Funds To Progress Promising HPV, Other Projects
Orphan Drugs Korean Pharmas’ Ticket To Global Success?
Kolon Ramps Up For Novel Osteoarthritis Cell Therapy


Related Companies